Cronos Group Inc · TSX:CRON
Cronos — Q3 2026 Earnings Presentation
29 slides from Cronos's earnings presentation, Nov 5, 2026
Slide 1: Investor Presentation November 2026
I N V E S T O R P R E S E N TAT I O N NOVEMBER 2026
Slide 2: Disclaimers & Cautionary Statements
D I S C L A I M E R S & C AU T I O N A R Y S TAT E M E N T S CRONOS GROUP INC. This document may contain forward-looking information or forward-looking statements within the Management defines Adjusted EBITDA as net income (loss) before interest, tax expense (benefit), meaning of applicable U.S. and
Slide 3: Agenda
I. Overview & Strategy AGENDA II. Borderless Products III. Regional Summary IV. Financial Summary V. Management Team and Board of Directors 3
Slide 4: Overview & Strategy
O V E R V I E W & S T R AT E GY Overview Strategy and Key Differentiators • Cronos is a global cannabis company focused on scaling leading • Leverage extensive investments in plant genetics, formulation, branded CPG products through R&D and innovation consumer insights and product design to build a
Slide 5: Borderless Products
BORDERLESS PRODUCTS 5
Slide 6: Building a Portfolio of Leading Brands
BUILDING A PORTFOLIO OF LEADING BRANDS BRAND VALUE MAINSTREAM PREMIUM MAINSTREAM VALUE POSITIONING Flower, Flower, Pre-Rolls, Flower, PRODUCT Pre-Rolls, Pre-Rolls, Vapes, Tinctures, Flower OFFERING Hash, Vapes, Edibles Pre-Rolls Edibles Edibles Netherlands: Canada: Israel: GEOGRAPHIC #1 Overall1 #2
Slide 7: Research & Development, Innovation
R E S E A R C H & D E V E LO P M E N T, I N N O VAT I O N Approach Edibles Flower Vapes • Leverage extensive R&D including robust consumer insights, sensory and testing to develop market-leading products with compelling value propositions • Continual iteration and improvement • SOURZ by Spinach • In
Slide 8: Industry-Leading Cultivation at Cronos GrowCo
I N D U S T R Y- L E A D I N G C U LT I VAT I O N AT C R O N O S G R O W C O Structure / Partnership Partner Background • 50% / 50% Joint Venture between • The Mucci Group is one of the largest Cronos and the Mucci Group greenhouse cultivators in North America o Cronos appoints 3 of 5 board members
Slide 9: Regional Summary
REGIONAL SUMMARY 9
Slide 10: Cronos Canada
CRONOS CANADA Overall Edibles Flower Vapes • Spinach achieved #1 flower market share in Canada in 20241 • Cronos’ flagship brand • Clear leadership position • Climbing the ranks in vapes, Spinach has #2 overall in edibles with SOURZ by • Supply constraints led to a now at #1 nationwide,1 with market
Slide 11: Cronos Israel
CRONOS ISRAEL • Cronos established its Israel business in 2017, received licensure in 2018 and launched the PEACE NATURALS Cronos Israel Quarterly Net Revenue brand in pharmacies in 2020 US$16M US$14M • Cronos Israel has established itself as the clear leader in the country1 US$12M US$10M • Israel-b
Slide 12: Cronos Netherlands (CanAdelaar)
C R O N O S N E T H E R L A N D S (C A N A D E L A A R ) Acquisition details Adult-Use Pilot Program Overview / Team / Facility Market Position • Pilot involves supplying • Founded in 2018, received • Only industrial-scale coffee shops in ten licensure in 2Q23, greenhouse producer in municipalities
Slide 13: Other International Markets
OT H E R I N T E R N AT I O N A L M A R K E T S • PEACE NATURALS continues Other Countries Quarterly Revenue to expand its reach across international markets US$14M • With recently completed expansion at US$12M Cronos GrowCo, targeting continued US$10M strong growth across these markets, in particul
Slide 14: Financial Summary
FINANCIAL SUMMARY 14
Slide 15: Net Revenue Trajectory
N E T R E V E N U E T R A J E C TO R Y Quarterly Net Revenue by Market $63.5M Canada Israel Other countries US$60M $13.2M $53.0M US$50M $9.3M $44.5M $45.2M $4.8M $5.7M $15.1M $36.3M US$40M $34.3M $33.5M $1.9M $15.0M $32.3M $11.8M $2.9M $30.3M $14.2M $27.8M $2.9M $4.9M $25.3M $2.8M $11.4M US$30M $24.
Slide 16: Gross Profit and Gross Margin Trajectory
G R O S S P R O F I T A N D G R O S S M A R G I N T R A J E C TO R Y Quarterly Adjusted Gross Profit1 and Trailing-12-Month (“TTM”) Adjusted Gross Margin2 47% 50% Adj Gross Profit (Left Axis) TTM Adj Gross Margins (Right Axis) 46% US$30M 42% 43% 43% 45% 37% 40% US$25M 32% 35% US$20M 30% 26% $32.3M 2
Slide 17: Disciplined OpEx Management
DISCIPLINED OPEX MANAGEMENT Quarterly OpEx1 and Trailing-12-Month (“TTM”) OpEx1 as % of Net Revenue US$30M 132% 130% Quarterly Adj OpEx(1) (Left Axis) 140% TTM Adj OpEx(1) as % of Net Revenue (Right Axis) 117% Cronos GrowCo OpEx and Net Revenue was 120% US$25M consolidated beginning in 3Q24 105% 93%
Slide 18: EBITDA and Cash Flow Trajectory
EBITDA AND CASH FLOW TRAJECTORY Quarterly Adj EBITDA, OCF Excl. Chg in WC1 and Free Cash Flow (“FCF”) Excl. Chg in WC2 US$24M Adj EBITDA OCF excluding Changes in Working Capital US$20M FCF excluding Changes in Working Capital US$16M No Debt; Current Cash, Cash Equivalents and Interest-Bearing US$12M
Slide 19: Management Team & Board of Directors
MANAGEMENT TEAM & BOARD OF DIRECTORS 19 19
Slide 20: Management Team
MANAGEMENT TEAM Our management team is a group of passionate, daring people, driven by quality and integrity, who are determined to write history, not read about it. MIKE GORENSTEIN JEFF JACOBSON SHANNON BUGGY ANNA SHLIMAK Chairman, President and Chief Growth Officer SVP, Global Head of People Chief
Slide 21: Board of Directors
B O A R D O F D I R E C TO R S DARREN MIKE GORENSTEIN JIM RUDYK JASON ADLER MURRAY GARNICK DOMINIK MEIER ELIZABETH SEEGAR BROUGHTON Chairman, President and Lead Director, Audit Committee, Audit Committee Compensation Chief Executive Officer Audit Committee Chair, Compensation Committee Darren Brough
Slide 22: Strategic Investment
S T R AT E G I C I N V E S T M E N T Exclusive partnership with cross-industry leader with highly relevant capabilities Proven expertise in responsible brand management and product distribution Leading portfolio of cannabis brands Financial capacity and wherewithal to support growth plan and capital
Slide 23: Thank You
CRONOS uss rrocvence ERM THANK YOU
Slide 24: Adjusted EBITDA Reconciliations: 9M2025 and 9M2026
ADJUSTED EBITDA RECONCILIATIONS: 9M2025 AND 9M2026 Reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures for prior reporting periods are provided in the Company’s earnings releases available at https://ir.thecronosgroup.com I. For the nine months ended Septembe
Slide 25: Adjusted EBITDA Reconciliations: FY2024 and FY2025
ADJUSTED EBITDA RECONCILIATIONS: FY2024 AND FY2025 Reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures for prior reporting periods are provided in the Company’s earnings releases available at https://ir.thecronosgroup.com (i) For the year ended December 31, 2
Slide 26: Adjusted Gross Profit Reconciliations: Q3 and 9M
ADJUSTED GROSS PROFIT RECONCILIATIONS: Q3 2025, Q3 2026, 9M2025 AND 9M2026 Reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures for prior reporting periods are provided in the Company’s earnings releases available at https://ir.thecronosgroup.com (i) Gross mar
Slide 27: Adjusted Gross Profit Reconciliations: Q4 and FY
ADJUSTED GROSS PROFIT RECONCILIATIONS: Q4 2024, Q4 2025, FY2024 AND FY2025 Reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures for prior reporting periods are provided in the Company’s earnings releases available at https://ir.thecronosgroup.com (i) Gross mar
Slide 28: Reconciliations: Total Operating Expenses to Operating Expenses Less Restructuring and Impairment
RECONCILIATIONS: TOTAL OPERATING EXPENSES TO OPERATING EXPENSES LESS RESTRUCTURING AND IMPAIRMENT COSTS Twelve Months Ended: Three Months Ended: December 31, December 31, December 31, March 31, June 30, September 30, 2023 2024 2025 2026 2026 2026 Total Operating Expenses 96,709 101,727 80,154 20,986
Slide 29: Reconciliations: Operating Cash Flow to OCF and FCF Excluding WC Changes
RECONCILIATIONS: OPERATING CASH FLOW (“OCF”) TO OCF AND FCF EXCLUDING WC CHANGES Twelve Months Ended: Three Months Ended: December 31, December 31, December 31, March 31, June 30, September 30, 2023 2024 2025 2026 2026 2026 Operating Cash Flow ("OCF") (42,835) 18,843 25,866 10,898 24,010 34,336 Chan